TNFRSF11A and neoplasm: A phase II study investigated denosumab alone in patients with relapsing/refractory OS was inadequate in this setting.[9] In patients who are nonresponders to conventional chemotherapy, combining neoadjuvant chemotherapy regimens with targeted agents, such as RANKL-directed antibodies might improve survival.[9] Denosumab is a human monoclonal antibody that inhibits bone resorption, increases new bone formation and delays tumor progression by binding to RANKL and preventing its interaction with RANK, thus mimicking the action of osteoprotegerin.